Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 177,995 |
|
|||||
| News | (1) | ||||||
| Day High | 237.53 | Low High |
|||||
| Day Low | 234.47 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| United Therapeutics Corporation | UTHR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.775 | -0.33% | 235.175 | 15:06:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 236.59 | 234.47 | 237.53 | 235.95 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,036 | 177,995 | $ 235.71 | $ 41,955,144 | - | 204.44 - 261.54 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:06:55 | 6 | $ 235.15 | USD |
United Therapeutics (UTHR) Options Flow Summary
United Therapeutics Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 11.03B | 47.06M | - | 2.33B | 984.8M | 20.93 | 11.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
United Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical UTHR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 237.47 | 241.00 | 233.275 | 236.00 | 557,083 | -2.29 | -0.97% |
| 1 Month | 228.03 | 241.37 | 221.53 | 234.37 | 497,904 | 7.15 | 3.13% |
| 3 Months | 215.27 | 250.89 | 208.6249 | 231.59 | 481,097 | 19.91 | 9.25% |
| 6 Months | 223.64 | 258.31 | 208.6249 | 229.87 | 402,019 | 11.54 | 5.16% |
| 1 Year | 225.45 | 261.54 | 204.44 | 227.93 | 369,149 | 9.73 | 4.31% |
| 3 Years | 209.05 | 283.09 | 158.38 | 218.44 | 400,767 | 26.13 | 12.50% |
| 5 Years | 102.18 | 283.09 | 74.31 | 169.79 | 429,373 | 133.00 | 130.16% |
United Therapeutics Description
| United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. |
